Parkinson disease with REM sleep behavior disorder Features, α-synuclein, and inflammation

Objectives:To investigate clinical features and potential mechanisms involving -synuclein oligomer and inflammation in patients with Parkinson disease (PD) and probable REM sleep behavior disorder (PRBD).Methods:We used the REM Sleep Behavior Disorder Screening Questionnaire (RBDSQ) to evaluate patients with PD and classified each as PRBD or not probable (NPRBD). Data collection included demographic information and evaluation of clinical symptoms using a series of rating scales. We tested for -synuclein oligomer and inflammatory factors in CSF and serum. Data analyses included comparisons between PRBD and NPRBD groups and correlation analyses among RBDSQ score and levels of the above factors.Results:The frequency of PRBD in patients with PD was 30.67%. The PRBD group had longer disease duration, more advanced disease stage, more severe motor symptoms, and other more severe nonmotor symptoms, including depression, anxiety, and fatigue. Levels of -synuclein oligomer in CSF and serum in the PRBD group were elevated compared with NPRBD and control groups. RBDSQ score was increased with the elevated -synuclein oligomer level in CSF, interleukin 1 and nitric oxide levels in CSF, and prostaglandin E-2 level in serum in the PD group. The level of -synuclein oligomer in CSF was enhanced with the deterioration of motor symptoms, and the elevated levels of interleukin 1, nitric oxide, and tumor necrosis factor in CSF in the PRBD group.Conclusions:PRBD is common in patients with PD, especially those with longer disease duration and more severe motor and nonmotor symptoms. Elevated -synuclein levels in CSF and serum may be correlated with PRBD through inflammation in central and peripheral nervous systems.